Lishan Biotech is a clinical-stage biotechnology company pioneering next-generation microbiome-based therapeutics for complex chronic diseases—including inflammatory disorders, oncology, and neurological conditions—where significant unmet medical needs persist worldwide.

We pursue a dual-engine innovation strategy: Live Biotherapeutic Products (LBPs) + Targeted Small Molecules. This integrated approach enables comprehensive modulation of the host-microbiome axis, spanning microbial ecosystem regulation to precise host pathway intervention, thereby redefining the frontier of microbiome medicine.

At the core of our R&D engine is IMicAP™, our proprietary AI- and data-driven Intelligent Microbiome Application Platform. IMicAP™ powers a closed-loop discovery-to-clinical workflow—from multi-omics research and computational target identification to mechanism validation and clinical translation.

Our pipeline is strategically focused on three interconnected therapeutic areas: Inflammatory Bowel Disease (IBD), Metabolism, and Oncology. Leveraging globally competitive targets and novel mechanisms of action, we aim to deliver First-in-Class or Best-in-Class therapies with transformative potential for patients around the world.

Guided by scientific rigor and patient-centric values, Lishan Biotech is accelerating the promotion of microbiome therapeutics on a global scale.